fashion -WSS

fashion

author：fashion 2025-08-12 08:27:58 - browse：34

Adam's take main illustration — Molly Ferguson/STAT

Annovis Bio had my biotech bull%^&! meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. But then I got an extraordinary explanation from CEO Maria Maccecchini. Now, I’m less worried about data spin because, by her own admission, the odds that the study succeeds, post endpoint change, are a lot lower.

Results from the completed Parkinson’s study, which is investigating Annovis’ drug called buntanetap, are well past due because of what the company has described as ongoing “data cleaning efforts.” The delay was announced on Jan. 24. Two weeks later, on Feb. 6, the primary efficacy endpoint of the study was changed, according to an update posted to the U.S. government’s clinical trials database.

Red flag, I thought, until I emailed Maccecchini, asking for an explanation. In response, she told me Annovis made the key endpoint change in August, based on a recommendation from officials at the Food and Drug Administration after the agency had reviewed data from an interim analysis of the study. It took the company another six months to update the study design in the ClinicalTrials.gov database, for reasons she did not explain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Why doctors need education on FDA device approval process

WSS

Dewpoint Therapeutics lays off staff after losing partnerships

Ending health disparities requires full federal government, panel says

Will biotech layoffs continue through 2023?

Interest rates are at a 22

Ending health disparities requires full federal government, panel says

Trump allegedly attempted to have surveillance video deleted: Special Counsel

focus

fashion

hotspot

Walensky prepares to leave CDC — and Congress — behind

Interest rates are at a 22

Trump demands the U.S. pay no more for drugs than other countries … again

American Airlines has a tentative contract deal with its pilots. Southwest is still negotiating

Trump demands the U.S. pay no more for drugs than other countries … again

Ford recalls 870K F

Trump demands the U.S. pay no more for drugs than other countries … again

Independent physicians launch a new lobbying group

At least 13 dead in Texas as scorching temps continue

Public health communication lessons from Covid

focus

EU regulator recommends expanding Mounjaro approval to obesity

Ford recalls 870K F

Interest rates are at a 22

Readout Newsletter: Merck, J&J, and long Covid

Stoke drug shows lower activity against childhood epilepsy

My yearlong odyssey to get my son’s ADHD medication covered

leisure time

Wikipedia

focus

focus